Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Ardelyx Inc. (NASDAQ:ARDX) shares are down during Friday’s premarket session following a recent financial update for the fourth quarter of 2025.Ardelyx reported breakeven versus the consensus earnings of 1 cent. Sales reached $125.22 million, beating the consensus of $118.13 million.Lead Drugs PerformanceThe company reported that IBSRELA (tenapanor) revenue grew 73% in 2025 to $274.2 million, contributing to total revenues of $407.3 million. The company recorded $86.6 million in IBSRELA revenue in the fourt ...